Protedyne Completes Installation of BioCube System at Correlagen
News Feb 15, 2006
Correlagen selected the BioCube System to automate their Genes That Matter™ gene testing service. The BioCube System will optimize their clinical workflow for throughput, analytical procedures, and data handling needs.
The BioCube System will integrate PCR setup, PCR cleanup, sequencing reaction setup, and sequencing reaction cleanup in a continuous process.
"We are pleased to have provided Correlagen with technology that addresses their need to automate complex testing protocols as well as the throughput requirements for their molecular diagnostic test menu," said Fran Tutttle, President and CEO of Protedyne. "We look forward to being a part of their future success."
"Protedyne’s BioCube System is proving to be an excellent platform for implementing Correlagen’s software and gene sequencing methods," said David Margulies, M.D., CEO of Correlagen.
"Our throughput, quality, and costs are unmatched, and the BioCube System is a major component of our success."
"Correlagen’s alliance program with academic and pharmaceutical collaborators is based in large part on the capabilities we have created on this automated platform," added Joyce Samet, Senior Vice President. "Correlagen looks forward to extending our relationship with Protedyne."
New Inherited Neurodevelopmental Disease DiscoveredNews
Researchers have identified a new inherited neurodevelopmental disease that causes slow growth, seizures and learning difficulties in humans.READ MORE
Bird and Turtle Chromosomes Help Identify Dinosaur DNANews
Researchers have used bird and turtle DNA to extrapolate the chromosome structure of their common ancestor that lived around 260 million years ago – 20 million years before the dinosaurs first emerged. They were then able to trace the evolution of avian and non-avian dinosaur DNA through to the present day.
Over 130 Glaucoma Gene Variants Could Help Predict BlindnessNews
An international study has identified 133 genetic variants that could help predict the risk of developing glaucoma, the world’s leading cause of incurable blindness. The findings are an advance in the fight to tackle the incurable, degenerative condition, which has virtually no symptoms in the early stages, and could lead to a genetic-based screening program.READ MORE